<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8610688</journal-id>
<journal-id journal-id-type="pubmed-jr-id">5937</journal-id>
<journal-id journal-id-type="nlm-ta">Mov Disord</journal-id>
<journal-id journal-id-type="iso-abbrev">Mov. Disord.</journal-id>
<journal-title-group>
<journal-title>Movement disorders : official journal of the Movement Disorder Society</journal-title>
</journal-title-group>
<issn pub-type="ppub">0885-3185</issn>
<issn pub-type="epub">1531-8257</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29644724</article-id>
<article-id pub-id-type="pmc">6105539</article-id>
<article-id pub-id-type="doi">10.1002/mds.27315</article-id>
<article-id pub-id-type="manuscript">NIHMS933343</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A novel missense mutation in <italic>GRIN2A</italic> causes a non-epileptic neurodevelopmental disorder</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Fernández-Marmiesse</surname>
<given-names>Ana</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN2">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kusumoto</surname>
<given-names>Hirofumi</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="author-notes" rid="FN2">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rekarte</surname>
<given-names>Saray</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Roca</surname>
<given-names>Iria</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Jin</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Myers</surname>
<given-names>Scott J.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Traynelis</surname>
<given-names>Stephen F.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Couce</surname>
<given-names>Ma Luz</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gutierrez-Solana</surname>
<given-names>Luis</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yuan</surname>
<given-names>Hongjie</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Unit for the Diagnosis and Treatment of Congenital Metabolic Diseases, Clinical University Hospital of Santiago de Compostela, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Galicia, Spain; Centro de Investigación Biomédica de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain</aff>
<aff id="A2">
<label>2</label>Department of Pharmacology, Emory University School of Medicine, Rollins Research Center, Atlanta, GA, 30322, USA</aff>
<aff id="A3">
<label>3</label>Unit of Child Neurology, Department of Pediatrics, Hospital Infantil Universitario Niño Jesús de Madrid, Madrid, Spain</aff>
<aff id="A4">
<label>4</label>Department of Neurology, the First Hospital of Shanxi Medical University, Taiyuan, 030001, China</aff>
<aff id="A5">
<label>5</label>Center for Functional Evaluation of Rare Variants (CFERV), Emory University School of Medicine, Atlanta, GA, 30322, USA</aff>
<author-notes>
<corresp id="FN1">Corresponding author: Ana Fernández-Marmiesse, Unit for the Diagnosis and Treatment of Congenital Metabolic Diseases, Clinical University Hospital of Santiago de Compostela, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Galicia, Spain. Phone: 0034-981950102; <email>amarmiesse@gmail.com</email></corresp>
<fn fn-type="equal" id="FN2">
<label>*</label>
<p>These authors contributed equally to this work</p>
</fn>
<fn fn-type="COI-statement" id="FN3">
<p><bold>Competing Financial Interests:</bold> S.F.T. is a consultant for Janssen Pharmaceuticals, Inc., Boehringer Ingelheim Pharma GmbH &amp; Co. KG, a member of the Scientific Advisory Board of Sage Therapeutics, and a co-founder of NeurOp Inc.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>9</day>
<month>1</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>11</day>
<month>4</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>7</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>7</month>
<year>2019</year>
</pub-date>
<volume>33</volume>
<issue>6</issue>
<fpage>992</fpage>
<lpage>999</lpage>
<!--elocation-id from pubmed: 10.1002/mds.27315-->
<abstract>
<sec id="S1">
<title>Background</title>
<p id="P1">Mutations in the <italic>GRIN2A</italic> gene, which encodes the GluN2A subunit of the N-methyl-D-aspartate receptor, have been identified in patients with epilepsy-aphasia spectrum disorders, idiopathic focal epilepsies with centrotemporal spikes, and epileptic encephalopathies with severe developmental delay. However, thus far, mutations in this gene have not been associated with a non-epileptic neurodevelopmental disorder with dystonia.</p>
</sec>
<sec id="S2">
<title>Objectives</title>
<p id="P2">To identify the disease-causing gene in two siblings with a neurodevelopmental and movement disorder with no epileptiform abnormalities.</p>
</sec>
<sec id="S3">
<title>Methods</title>
<p id="P3">Targeted next-generation sequencing panel for neuropediatric disorders and subsequent electrophysiological studies.</p>
</sec>
<sec id="S4">
<title>Results</title>
<p id="P4">The two siblings carry a novel missense mutation in the <italic>GRIN2A</italic> gene (p. Ala643Asp) that was not detected in genomic DNA isolated from blood cells of their parents, suggesting that the mutation is the consequence of germinal mosaicism in one progenitor. In functional studies, the GluN2A-A643D mutation increased the potency of the agonists L-glutamate and glycine and decreased the potency of endogenous negative modulators, including protons, Mg<sup>2+</sup>, and Zn<sup>2+</sup>, but reduced agonist-evoked peak current response in mammalian cells, suggesting that this mutation has a mixed effect on NMDAR function.</p>
</sec>
<sec id="S5">
<title>Conclusion</title>
<p id="P5"><italic>De novo GRIN2A</italic> mutations can give rise to a neurodevelopmental and movement disorder without epilepsy.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Glutamate receptor</kwd>
<kwd>NMDA receptor</kwd>
<kwd>
<italic>GRIN2A</italic>
</kwd>
<kwd>GluN2A</kwd>
<kwd>movement disorder</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>